Navigation Links
Penwest Pharmaceuticals Announces Intention to Terminate NASDAQ Listing and Registration
Date:10/15/2010

PATTERSON, N.Y., Oct. 15 /PRNewswire-FirstCall/ -- Penwest Pharmaceuticals (Nasdaq: PPCO) ("Penwest") today announces its intention to strike the shares of its common stock from listing and registration on The NASDAQ Stock Market ("NASDAQ"). Penwest intends to take this action in connection with the anticipated merger (the "Merger") of West Acquisition Corp. ("Merger Sub"), an indirect wholly-owned subsidiary of Endo Pharmaceuticals Holdings Inc. ("Endo") (Nasdaq: ENDP), with and into Penwest pursuant to the Agreement and Plan of Merger among Penwest, Merger Sub and Endo, dated August 9, 2010. As previously announced, a special meeting of Penwest shareholders will be held on November 4, 2010 to approve the Merger. Endo and its affiliates own approximately 90.56% of Penwest common stock, and their shares represent sufficient votes to approve the Merger. Penwest intends to consummate the Merger as soon as possible following shareholder approval pursuant to applicable law. Following the completion of the Merger, shares of Penwest common stock will no longer be listed or registered on NASDAQ, or any other stock exchange or quotation system, and upon application to the SEC will be deregistered under the Exchange Act of 1934. Following the completion of the Merger, Penwest will no longer be a public company.

About Penwest

Penwest is a drug development company focused on identifying and developing products that address unmet medical needs, primarily for rare disorders of the nervous system. We are currently developing A0001, or a-tocopherolquinone, a coenzyme Q analog, for inherited mitochondrial respiratory chain diseases. We are also applying our drug delivery technologies and drug formulation expertise to the formulation of product candidates under licensing collaborations.

SOURCE Penwest Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Penwest Pharmaceuticals
2. ISTA Pharmaceuticals Announces Conference Call and Webcast of Third Quarter 2010 Financial Results
3. Isis Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Syndax Pharmaceuticals Announces Issuance of UK Patent for Entinostat
5. Anadys Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
6. Cumberland Pharmaceuticals and Phebra Pty Ltd. Announce the Launch of AcetadoteĀ® in Australia
7. Prolong Pharmaceuticals Secures $30 Million in Funding
8. Amylin Pharmaceuticals to Webcast Third Quarter Results
9. Lexicon Pharmaceuticals to Present at BioCentury Newsmakers in the Biotech Industry Conference Oct. 22nd
10. Titan Pharmaceuticals Announces Journal of the American Medical Association Publication of Phase 3 Probuphineā„¢ Data
11. Cempra Pharmaceuticals Names Richard Kent, M.D., to Its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Humberto C. Antunes,  Galderma  worldwide CEO, will receive a ... of Drugs in Dermatology (JDD) at the upcoming ... is January 17-20, 2014, at the Omni Orlando Resort at ChampionsGate ... The ODAC is a distinguished event that delivers a ...
(Date:1/15/2014)... R.I. , Jan. 15, 2014 MultiCell Technologies, ... filed a U.S. provisional patent application concerning composition of ... to achieve targeted tumor cell death.  ... small noncoding double stranded RNA molecules (VSRNAs) which interfere ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... 15, 2011 Echo Therapeutics, Inc. (OTC Bulletin Board: ... tCGM System as a non-invasive, wireless, transdermal continuous glucose ... transdermal drug delivery, today announced the appointment of William ... of Directors.  Echo,s Board now has a majority of ...
... 2011 Joyant Pharmaceuticals Inc. ("Joyant"), a privately-held pharmaceutical ... covering an entire class of anti-cancer therapeutics based upon ... targeting the apoptotic pathway and have broad potential for ... malignancies. The United States Patent and Trademark ...
Cached Medicine Technology:Echo Therapeutics Announces Appointments to Board of Directors 2Echo Therapeutics Announces Appointments to Board of Directors 3
(Date:4/17/2014)... MAYWOOD, Il. (April 17, 2014) Doctors who ... disease called lymphangioleiomyomatosis (LAM) can face an agonizing ... progression of the disease and help relieve shortness ... lung transplants, and sirolimus can cause potentially fatal ... said pulmonologist Dr. Daniel Dilling, medical director of ...
(Date:4/17/2014)... 2014-- Colic affects about one in five infants in ... visits during the first several months after birth. Research ... showing promise; however, the April 1, 2014 issue of ... reported on a study, "Probiotics and Infant Colic," concluding ... for infant colic did not reduce crying ...
(Date:4/17/2014)... EcoHealth Alliance, a nonprofit organization that focuses on conservation ... today examining the current state of knowledge of the ... improved global surveillance strategies to combat the emergence of ... in West Africa that has claimed the lives of ... According to the World Health Organization (WHO), the ...
(Date:4/17/2014)... Arias, M.D., Ph.D., at The University of Texas Health ... superbug that caused a bloodstream infection in a Brazilian ... of The New England Journal of Medicine . ... of highly-resistant bacteria known as methicillin-resistant Staphylococcus aureus ... hospital and community-associated infections. The superbug has also acquired ...
(Date:4/17/2014)... April 17, 2014 Meaningful long-term survival is ... of the abdomen when treated with cytoreductive surgery ... a first-of-its-size analysis by physicians at Wake Forest ... the largest reported, single-center experience with cytoreductive surgery ... M.D., and analysis of 20 years, worth of ...
Breaking Medicine News(10 mins):Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:New MRSA superbug emerges in Brazil 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2
... of the 1000 Genomes Project announced today that three ... have joined the international effort to build the most ... a tool for medical research. The new participants are: ... Biosystems, an Applera Corp. business, Foster City, Calif.; and ...
... Science,(Nasdaq: CSCX ), a global leader ... products, announced today,that it completed certification for ... Electronic Health Record (EHR)., (Logo: ... player in electronic health systems, with more,than ...
... children may have an impact on cardiovascular functioning equivalent ... to a research abstract that will be presented Wednesday ... Associated Professional Sleep Societies (APSS). , The study, authored ... Melbourne and Monash University, Melbourne, Victoria, Australia, focused on ...
... Ill. Widowed seniors are more likely to have disrupted ... event, according to a research abstract that will be presented ... the Associated Professional Sleep Societies (APSS). , The study, authored ... focused on 28 spousally bereaved seniors aged 60 years and ...
... insomnia delivered via the Internet can significantly improve insomnia ... be presented on Wednesday at SLEEP 2008, the 22nd ... , The study, authored by Lee Ritterband, PhD, of ... female) with an average age of 45 years. ...
... DaVita Inc., a leading,provider of kidney care ... disease (CKD), recently announced that Debbie Benner, MA, ... and Mary,Burgess, RD, Grant Program Manager for DaVita ... at the XIV International Congress on,Nutrition and Metabolism ...
Cached Medicine News:Health News:3 sequencing companies join 1000 Genomes Project 2Health News:3 sequencing companies join 1000 Genomes Project 3Health News:3 sequencing companies join 1000 Genomes Project 4Health News:3 sequencing companies join 1000 Genomes Project 5Health News:HeartCentrix Informatics Solution from Cardiac Science Now Certified with Allscripts Electronic Health Records 2Health News:HeartCentrix Informatics Solution from Cardiac Science Now Certified with Allscripts Electronic Health Records 3Health News:Primary snoring in children impacts cardiovascular functioning 2Health News:Primary snoring in children impacts cardiovascular functioning 3Health News:Disturbed sleep is prevalent in widowed seniors 2Health News:A self-help program delivered online can improve insomnia in adults 2Health News:DaVita Dietitians to Speak at the International Congress on Nutrition and Metabolism in Renal Disease in France 2
... MICROSTAAR injector contains a plunger style advance, ... be resterilized for multiple use. The injector ... accepts only STAAR cartridges. These injectors are ... This system was designed specifically ...
... the fundamental capsulotmy laser - the unique Ultra ... 2855% less energy in air at approximately 1.8 ... This technology eliminates the occurrence of hot ... pitting. , , , Ultra Q ...
... system is an innovative, robust and ... excellent clinical performance. The digital broadband ... the ES500 system deliver excellent tissue ... system offers a full suite of ...
Protects the eye during or after surgery or trauma. 8mm diameter, lint free keeps cornea moist. Protects retina from operating microscope light rays....
Medicine Products: